Oncorus Inc. (ONCR): Price and Financial Metrics

Oncorus Inc. (ONCR): $0.46

0.01 (+2.07%)

POWR Rating

Component Grades













Add ONCR to Watchlist
Sign Up

Industry: Biotech



in industry

ONCR Stock Price Chart Interactive Chart >

Price chart for ONCR

ONCR Price/Volume Stats

Current price $0.46 52-week high $6.08
Prev. close $0.45 52-week low $0.41
Day low $0.45 Volume 69,000
Day high $0.50 Avg. volume 131,731
50-day MA $0.69 Dividend yield N/A
200-day MA $1.26 Market Cap 11.93M

Oncorus Inc. (ONCR) Company Bio

Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.

ONCR Latest News Stream

Event/Time News Detail
Loading, please wait...

ONCR Latest Social Stream

Loading social stream, please wait...

View Full ONCR Social Stream

Latest ONCR News From Around the Web

Below are the latest news stories about ONCORUS INC that investors may wish to consider to help them evaluate ONCR as an investment opportunity.

Oncorus to Participate in Upcoming Investor Conferences

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences: Evercore ISI 5th Annual HealthCONx Conference: Virtual fireside chat on Thursday, December 1, 2022 at 10:55 a.m. ET.Piper Sandler 34th Annual Healthcare Conference

Yahoo | November 23, 2022

Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting

ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in glioblastoma multiforme (GBM); data show that the canonical entry receptor for HSV-1, NECTIN-1, is only minimally expressed in human GBM tumors. ONCR-719 expresses four immunomodulatory payloads, including IL-12, an anti-PD-1 nanobody, 15-hydroxyprostaglandin dehydrogenase (HPGD), and a novel macrophage-modulating Fc-enhanced antibody to reverse GBM’s immunosu

Yahoo | November 18, 2022

Oncorus (ONCR) Gets a Buy from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Oncorus (ONCR - Research Report), with a price target of $7.00. The company's shares closed last Friday at $0.57.According to TipRanks, Ramakanth is an analyst with an average return of -13.5% and a 28.60% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as ImmunoGen, MiMedx Group, and Rewalk Robotics.Currently, the analyst consensus on Oncorus is a Moderate Buy with an average price target of $6.50, implying a 1,033.39% upside from current levels. In a report released on November 2, Piper Sandler also maintained a Buy rating on the stock with a $6.

Howard Kim on TipRanks | November 7, 2022

Oncorus, Inc. (ONCR) Moves to Buy: Rationale Behind the Upgrade

Oncorus, Inc. (ONCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | November 7, 2022

Recap: Oncorus Q3 Earnings

Oncorus (NASDAQ: ONCR ) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Oncorus missed estimated earnings by 1.33%, reporting an EPS of $-0.76 versus … Full story available on Benzinga.com

Benzinga | November 2, 2022

Read More 'ONCR' Stories Here

ONCR Price Returns

1-mo -19.79%
3-mo N/A
6-mo -72.12%
1-year -91.86%
3-year N/A
5-year N/A
YTD -91.27%
2021 -83.70%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5925 seconds.